SJEPD032407_D2.RNA-Seq
EPN · Anaplastic EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Anaplastic EPN
- cancer_type
- EPN
- subtype
- Anaplastic EPN
- age_years
- 1.15
- e1_e2
- E2
- umap1_2d
- -5.565149587
- umap2_2d
- 2.464030566
- umap1_3d
- -1.141132773
- umap2_3d
- 4.173328361
- umap3_3d
- -0.797802849
- dataset
- EPN-StJude
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4SCWT0FX | EPN | EPN Tumor | 0.822 |
| 2 | DRR168611 | — | — | 0.803 |
| 3 | TCGA-OR-A5KZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.790 |
| 4 | TCGA-91-6831-01A-11R-1858-07 | — | cohortA3 | 0.775 |
| 5 | BS_VT6C6N6K | medulloblastoma | — | 0.772 |
| 6 | SRR6013562 | — | cohortSQ2 | 0.761 |
| 7 | MNG737 | — | — | 0.759 |
| 8 | BS_1EBQ3T20 | high-grade glioma | — | 0.757 |
| 9 | BS_TZ5D0A7R | EPN | Supratentorial EPN | 0.756 |
| 10 | SAMN03290945 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.660 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |